Copyright
©The Author(s) 2020.
World J Clin Cases. Dec 26, 2020; 8(24): 6264-6273
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6264
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6264
HBsAb positive (n = 633) | HBsAb negative (n = 305) | Fisher P value | |
Time to reactivation | 197 (93-320) | 38.5 (7-178) | 0.1281 |
Reactivation rate within 6 mo (%) | 2.05 | 4.26 | 0.0459 |
- Citation: Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Risk factors for de novo hepatitis B during solid cancer treatment. World J Clin Cases 2020; 8(24): 6264-6273
- URL: https://www.wjgnet.com/2307-8960/full/v8/i24/6264.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i24.6264